Genovis

Genovis ROCE

The Return on Capital Employed (ROCE) of Genovis (GENO.ST) as of Oct 29, 2026 is 10.12 %. In the previous year, Return on Capital Employed (ROCE) was 20.06 % — a change of -49.53% (lower).

ROCE

10.12 %

YoY

-49.53%

Last updated:

In 2025, Genovis's return on capital employed (ROCE) was 10.12 %, a -49.53% increase from the 20.06 % ROCE in the previous year.

The Genovis ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-3.68 SEK
Jan 1, 2019
37.97 SEK
Jan 1, 2020
7.90 SEK
Jan 1, 2021
21.53 SEK
Jan 1, 2022
6.81 SEK
Jan 1, 2023
28.42 SEK
Jan 1, 2024
20.06 SEK
Jan 1, 2025
10.12 SEK
The Genovis ROCE history
YEARROCEYoY
10.12 %-49.53%
20.06 %-29.41%
28.42 %+317.26%
6.81 %-68.37%
21.53 %+172.51%
7.90 %-79.19%
37.97 %-1,130.43%
-3.68 %-91.45%
-43.08 %-54.66%
-95.01 %-57.72%
-224.72 %+60.08%
-140.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genovis Stock analysis

What does Genovis do? Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Genovis's Return on Capital Employed (ROCE)

Genovis's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Genovis's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Genovis's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Genovis’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Genovis stock

Return on Capital Employed (ROCE) of Genovis is 10.12 % in 2025.

Return on Capital Employed (ROCE) of Genovis changed from 20.06 % to 10.12 %, representing a -49.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Genovis since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Genovis with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genovis

All Key Metrics — Genovis